Skip to content
Peptide Atlas
All peptides

Tirzepatide

Tier 1 · Human trials
Also known as Mounjaro · Zepbound

Grounded in Tier 1 evidence: multiple phase 3 randomized controlled trials (SURPASS and SURMOUNT programmes, n from 24 up to ~2000 per trial), FDA prescribing information and regulatory documentation, and human pharmacokinetic/mass-balance studies. Lower-tier material is present and flagged: a peptide protocol wiki (single-source figures for molecular weight, receptor potency ratios, peak-plasma timing and storage) and a Tier 3 vendor article (detailed clearance modeling). Some efficacy signals derive from very small early trials (a 24-patient phase 1 trial), and cardiovascular benefit rests on pooled/observational analyses rather than a dedicated outcomes trial.

Half-life
~120 h
Routes
Subcutaneous injection
Goals
Weight management / obesity · Glycemic control / type 2 diabetes · Metabolic health · Cardiovascular risk · Liver health (MASH)
Cost / mg
Not recorded

How it works

According to a Tier 1 review, tirzepatide is a once-weekly injectable that activates two gut-hormone receptors at once — the GIP receptor and the GLP-1 receptor (a 'dual incretin' agonist). A review explains that GIP and GLP-1 are incretin hormones the intestine releases after eating; they prompt the pancreas to release insulin when blood glucose is high, and GLP-1 also reduces food intake and slows stomach emptying. A peptide protocol wiki describes how GLP-1 receptor activation by tirzepatide boosts glucose-dependent insulin secretion, lowers glucagon, slows gastric emptying and reduces appetite through the hypothalamus, while GIP receptor activation adds to insulin secretion, may improve lipid metabolism and fat distribution, and enhances central appetite control. A pharmacokinetic study reports the glucose-lowering effect may reflect GIP-receptor-mediated insulin action plus improved insulin sensitivity independent of weight change, while weight loss reflects combined GIP- and GLP-1-mediated effects on satiety and food intake.

Overview

Overview

A Tier 1 review describes tirzepatide as a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist. It is marketed as Mounjaro and Zepbound.

Reviews describe tirzepatide as a 39-amino-acid synthetic modified peptide based on the native GIP sequence, with a C20 (20-carbon) fatty diacid moiety attached via a linker at lysine-20 that enables albumin binding and prolongs its half-life to permit once-weekly dosing. A peptide protocol wiki lists its molecular weight as 4813.45 Da (a single-source figure).

How it works

A review notes that GIP and GLP-1 are incretin hormones released in the intestine in response to nutrient intake that stimulate pancreatic beta-cell insulin secretion, with GLP-1 also reducing food intake and delaying gastric emptying. According to a peptide protocol wiki, GLP-1R activation by tirzepatide enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and reduces appetite via hypothalamic signaling, while GIPR activation potentiates insulin secretion, may improve lipid metabolism and fat distribution, and enhances central appetite regulation. A pharmacokinetic study reports the glucose-lowering effect may reflect GIP-receptor-mediated insulinotropic action and increased insulin sensitivity independent of body weight changes, while weight loss may be attributed to combined GIP- and GLP-1-receptor-mediated regulation of satiety and food intake.

In vitro analysis reports tirzepatide engages the GIP receptor more than the GLP-1 receptor (an imbalanced mechanism), and that a peptide protocol wiki puts its potency at approximately 5-fold that of native GIP at the GIP receptor and about 0.2-fold that of native GLP-1 at the GLP-1 receptor (single-source figures). Studies in animal models of obesity and diabetes report that co-administration of GIP and GLP-1 has synergistic effects in reducing body weight, food consumption and fat mass. A review notes GIP and GLP-1 receptors are expressed in many organs with overlapping and nonoverlapping expression, giving tirzepatide pleiotropic effects on glycemic control, body weight, the cardiorenal system and lipid metabolism.

Regulatory status and indications

Sources report tirzepatide is approved (as Mounjaro) as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and is approved in Australia, Canada, the EU, the UK, the US and Japan. Sources state the FDA approved tirzepatide as Mounjaro in May 2022 for type 2 diabetes and as Zepbound in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. A review states the US FDA approved tirzepatide for moderate-to-severe obstructive sleep apnea in people with obesity in 2024. Sources state tirzepatide is not indicated for type 1 diabetes mellitus; it has demonstrated efficacy in weight loss leading to off-label use for obesity, and is under development/evaluation for further indications including nonalcoholic steatohepatitis.

Clinical evidence

Glycemic control (type 2 diabetes)

A review reports tirzepatide was evaluated in five published clinical trials (n=6278) within the SURPASS programme, demonstrating HbA1c improvements of –1.24% to –2.11% versus placebo and –0.6% to –1.14% versus active comparator, and weight loss of up to 15.5 kg. Phase 3 trials and reviews report tirzepatide significantly reduces glycated hemoglobin and body weight in patients with type 2 diabetes and is superior to a GLP-1 receptor agonist for glycaemic control and weight loss. A peptide protocol wiki states HbA1c reductions up to 2.58% in SURPASS trials and 1.87–2.07% in treatment-naive T2D in SURPASS-1.

A 40-week trial of 478 participants reported HbA1c decreased by 1.87% (5 mg), 1.89% (10 mg) and 2.07% (15 mg) versus +0.04% with placebo, with 87–92% meeting HbA1c <7.0% (vs 20% placebo) and dose-dependent bodyweight loss of 7.0–9.5 kg. A 40-week trial of 475 participants adding tirzepatide to insulin glargine reported HbA1c changes of −2.11% (5 mg), −2.40% (10 mg) and −2.34% (15 mg) versus −0.86% placebo, and body weight changes of −5.4 kg, −7.5 kg and −8.8 kg versus +1.6 kg placebo. A 52-week trial of 2002 participants reported HbA1c change of −2.43% (10 mg) and −2.58% (15 mg) versus −1.44% with insulin glargine.

A small early phase 1 trial of 24 randomized Chinese patients (22 completers) reported HbA1c fell from baseline by −2.4% in the 2.5–10.0 mg group at week 16 and −1.6% in the 2.5–15.0 mg group at week 24, with body weight decreasing −4.2 kg and −6.7 kg respectively; this trial's small size means its findings carry far less weight than the pivotal programmes.

Head-to-head versus semaglutide

A 40-week phase 3 trial of 1879 patients reported tirzepatide reduced HbA1c by −2.01% (5 mg), −2.24% (10 mg) and −2.30% (15 mg) versus −1.86% with semaglutide 1 mg, with 10 mg and 15 mg superior to semaglutide, and greater weight reductions (−1.9, −3.6 and −5.5 kg versus semaglutide). A randomized trial of 751 participants with obesity but without diabetes reported tirzepatide achieved −20.2% mean weight change at week 72 versus −13.7% with semaglutide, and −18.4 cm waist reduction versus −13.0 cm. A trial comparing tirzepatide 15 mg, semaglutide 1 mg and placebo at week 28 reported tirzepatide produced significant reductions in body weight and fat mass versus placebo and semaglutide, though appetite scores and energy intake reductions did not differ between the two drugs. Reviews report tirzepatide was superior to dulaglutide 0.75 mg, semaglutide 1 mg, and basal and prandial insulin for glycaemic control and weight loss.

Weight management

The SURMOUNT-1 trial reported mean weight loss over 72 weeks of about 15.0% at 5 mg, ~19.5–20.9% at 10 mg and 22.5% at 15 mg in adults with obesity but without type 2 diabetes, with 57% achieving ≥20% weight loss at 15 mg. The SURMOUNT-4 trial (n=670) reported a mean 20.9% reduction during a 36-week lead-in, then −5.5% with continued tirzepatide versus +14.0% with placebo over weeks 36–88 (difference −19.4%); 89.5% of tirzepatide participants maintained at least 80% of their lead-in loss versus 16.6% on placebo, and withdrawing tirzepatide led to substantial regain. A source summarizing SURMOUNT-4 notes those switched to placebo regained roughly two-thirds of what they had lost.

Other outcomes

A 52-week trial of 190 participants (157 evaluable biopsies) reported MASH resolution without worsening fibrosis in 44% (5 mg), 56% (10 mg) and 62% (15 mg) versus 10% placebo, and improvement of at least one fibrosis stage without worsening MASH in 51–55% of tirzepatide groups. A review reports tirzepatide improves blood pressure, reduces LDL cholesterol and reduces triglycerides. Reviews report benefits in metabolic dysfunction-associated steatohepatitis, heart failure with preserved ejection fraction, obesity, sleep apnea and diabetes prevention, plus potential cardiovascular benefits. A pooled analysis of seven RCTs (4,887 tirzepatide-treated, 2,328 control) reported hazard ratios versus controls of 0.80 (95% CI 0.57–1.11) for MACE-4, 0.90 for cardiovascular death and 0.80 for all-cause death, indicating no increased major cardiovascular event risk; the wide confidence intervals crossing 1 and the absence of a dedicated cardiovascular outcomes trial mean cardiovascular benefit is suggested rather than established.

Pharmacokinetics

Multiple sources report tirzepatide's plasma/elimination half-life as approximately 5 days (a Chinese trial reported 5–6 days). A population pharmacokinetic analysis of 19 pooled studies describes its PK as a two-compartment model with first-order absorption and elimination enabling sustained exposure with once-weekly subcutaneous dosing. A peptide protocol wiki states peak plasma concentrations occur at approximately 8–72 hours post-injection (single-source). A human mass-balance study reports most of an excreted dose was recovered within 480 h, with renal excretion the principal route (~66% urine, ~33% feces), no intact tirzepatide in urine or feces, and parent drug as the major circulating component. A pharmacokinetics review notes native human GLP-1 has a half-life of ~2 minutes and that structural modifications result in minimal metabolism and renal excretion. A drug-drug-interaction review reports no clinically significant enzyme- or transporter-mediated interactions, that mechanism-of-action interactions are limited to delayed gastric emptying and mostly clinically insignificant, but that significant changes in oral contraceptive exposure were observed following tirzepatide administration.

What the research shows

275 findings extracted from the 30 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 90 human trial findings, 4 human study findings and 1 expert opinion finding.

  • human trialSignificant glycemic and body weight reductions with tirzepatide treatments of 5, 10, or 15 mg once weekly have been consistently observed across a diverse T2DM population across several large clinical trials4

  • human trialThe drug leads to significantly improved glycemic control and weight reduction in patients with T2DM6

  • human trialSURPASS-5 clinical trial showed a -2.11% reduction in HbA1c levels at 5 mg per week dosing, compared to -0.86% with placebo6

  • human trialAt the highest dose of 15 mg per week, tirzepatide led to a -2.34% reduction in HbA1c over 40 weeks6

  • human trialA weight reduction of 5.4 kg was seen with 5 mg of tirzepatide dosing6

  • human trialA weight reduction of 10.5 kg was observed with 15 mg dosing6

  • human trialTirzepatide is superior to placebo in improving hemoglobin A1c (HbA1c) levels6

  • human trialTirzepatide yields clinically significant improvements in glycemic control and weight loss when compared with other GLP-1 receptor agonists (semaglutide and dulaglutide), insulin degludec, and insulin glargine6

Show the remaining 87

  • human trialDemonstrated up to 22.5% body weight reduction in clinical trials7

  • human trialSignificant HbA1c reduction (up to 2.58% in SURPASS trials)7

  • human trialHbA1c reductions of 1.87-2.07% in treatment-naive T2D (SURPASS-1)7

  • human trialIn the SURMOUNT-1 trial, patients on the highest dose lost an average of 22.5% of their body weight over 72 weeks8

  • human trialTirzepatide produces greater average weight loss than GLP-1-only drugs like semaglutide in available trial data8

  • human trialSURMOUNT-1 trial showed mean weight loss of 20.9% at 10 mg and 22.5% at 15 mg over 72 weeks8

  • human trialSURMOUNT-1 tested three maintenance doses — 5 mg, 10 mg, and 15 mg in adults with obesity but without type 2 diabetes8

  • human trialAt 5 mg mean weight loss was ~15.0%, at 10 mg ~19.5%, at 15 mg ~20.9% over 72 weeks8

  • human trialIn SURPASS trial program, tirzepatide outperformed semaglutide 1 mg on both HbA1c reduction and weight loss at all three doses8

  • human trialSURMOUNT-4 trial showed participants who continued tirzepatide lost an additional ~5.5% of body weight over 52 weeks8

  • human trialSURMOUNT-4 showed those who switched to placebo regained roughly two-thirds of what they'd lost8

  • human trialTirzepatide is highly effective for obesity management9

  • human trialSemaglutide is highly effective for obesity management9

  • human trialTirzepatide achieves -20.2% mean percent change in weight at week 72 compared to -13.7% with semaglutide9

  • human trialTirzepatide achieves -18.4 cm mean change in waist circumference compared to -13.0 cm with semaglutide9

  • human trialTirzepatide is superior to semaglutide for weight reduction in participants with obesity but without diabetes9

  • human trialTirzepatide is superior to semaglutide for waist circumference reduction9

  • human trialParticipants receiving tirzepatide were more likely to achieve weight reductions of at least 10%, 15%, 20%, and 25%9

  • human trialTirzepatide enables many to achieve ≥ 20% weight loss10

  • human trialTirzepatide results in clinically important improvements in sleep apnea10

  • human trialTirzepatide results in clinically important improvements in metabolic-dysfunction associated steatohepatitis10

  • human trialTirzepatide results in clinically important improvements in heart failure with preserved ejection fraction10

  • human trialTirzepatide results in clinically important improvements in diabetes prevention10

  • human trialTirzepatide with diet and physical activity maintains weight reduction in adults with obesity or overweight (BMI ≥30 or ≥27 with weight-related complication)12

  • human trialMean weight reduction of 20.9% achieved during 36-week open-label lead-in period with once-weekly subcutaneous tirzepatide (10 or 15 mg maximum tolerated dose)12

  • human trialMean percent weight change from week 36 to week 88 was -5.5% with tirzepatide vs 14.0% with placebo (difference -19.4%)12

  • human trial89.5% of tirzepatide-treated participants maintained at least 80% of weight loss during lead-in period at week 88, compared with 16.6% receiving placebo12

  • human trialOverall mean weight reduction from week 0 to 88 was 25.3% for tirzepatide and 9.9% for placebo12

  • human trialWithdrawing tirzepatide leads to substantial regain of lost weight12

  • human trial44% in the 5-mg tirzepatide group met criteria for resolution of MASH without worsening of fibrosis (difference vs. placebo 34 percentage points)13

  • human trial56% in the 10-mg tirzepatide group met criteria for resolution of MASH without worsening of fibrosis (difference vs. placebo 46 percentage points)13

  • human trial62% in the 15-mg tirzepatide group met criteria for resolution of MASH without worsening of fibrosis (difference vs. placebo 53 percentage points)13

  • human trial55% in the 5-mg tirzepatide group had improvement of at least one fibrosis stage without worsening of MASH (difference vs. placebo 25 percentage points)13

  • human trial51% in the 10-mg tirzepatide group had improvement of at least one fibrosis stage without worsening of MASH (difference vs. placebo 22 percentage points)13

  • human trial51% in the 15-mg tirzepatide group had improvement of at least one fibrosis stage without worsening of MASH (difference vs. placebo 21 percentage points)13

  • human trialOnce-weekly subcutaneous tirzepatide, as monotherapy or add-on-therapy to oral glucose-lowering medications and insulin, was superior to the GLP-1 receptor agonists dulaglutide 0.75 mg and semaglutide 1 mg as well as basal and prandial insulin for glycaemic control and weight loss in adults with inadequately controlled T2DM in phase III SURPASS trials14

  • human trialTirzepatide has been evaluated in five published clinical trials (n=6278) within the SURPASS clinical trial programme15

  • human trialTirzepatide trials demonstrated significant improvements in glycosylated haemoglobin (–1.24% to –2.11% versus placebo and –0.6% to –1.14% versus active comparator)15

  • human trialTirzepatide trials demonstrated weight loss up to 15.5 kg versus placebo or active comparator15

  • human trialTirzepatide exhibited superior glycaemic control and weight loss when compared directly with a GLP1RA15

  • human trialHbA1c decreased from baseline by −2.4% in the 2.5–10.0 mg tirzepatide group at week 1616

  • human trialHbA1c decreased from baseline by −1.6% in the 2.5–15.0 mg tirzepatide group at week 2416

  • human trialBody weight decreased from baseline by −4.2 kg at week 16 in the tirzepatide 2.5–10.0 mg group16

  • human trialBody weight decreased from baseline by −6.7 kg at week 24 in the 2.5–15.0 mg group16

  • human trialMean fasting plasma glucose levels fell from baseline by −4.6 mmol/L in the tirzepatide 2.5–10.0 mg group at week 1616

  • human trialMean fasting plasma glucose levels fell from baseline by −3.7 mmol/L at week 24 in the tirzepatide 2.5–15.0 mg group16

  • human trialEvidence from five SURPASS clinical trials has demonstrated that tirzepatide has potent glucose lowering and weight loss18

  • human trialGLP-1 therapy is associated with better glycemic control, weight reduction, and favorable cardiovascular outcomes18

  • human trialTirzepatide significantly reduces glycated hemoglobin levels and body weight in patients with T2DM as observed in phase 3 clinical trials19

  • human trialTirzepatide treatment demonstrated significant reductions in body weight compared with placebo and semaglutide20

  • human trialTirzepatide resulted in greater fat mass reduction compared with placebo and semaglutide20

  • human trialTirzepatide significantly reduced appetite versus placebo20

  • human trialSemaglutide significantly reduced appetite versus placebo20

  • human trialAppetite scores and energy intake reductions did not differ between tirzepatide and semaglutide20

  • human trialTirzepatide added to insulin glargine in patients with type 2 diabetes with inadequate glycemic control resulted in mean HbA1c change from baseline of -2.40% with 10-mg dose and -2.34% with 15-mg dose vs -0.86% with placebo at week 4021

  • human trialMean HbA1c change from baseline was -2.11% with 5-mg tirzepatide21

  • human trialMean body weight change from baseline was -5.4 kg with 5-mg tirzepatide, -7.5 kg with 10-mg tirzepatide, -8.8 kg with 15-mg tirzepatide and 1.6 kg with placebo21

  • human trial85%-90% of patients treated with tirzepatide achieved HbA1c less than 7% vs 34% with placebo21

  • human trialHR for MACE-4 (cardiovascular death, myocardial infarction, stroke and hospitalized unstable angina) comparing tirzepatide versus controls was 0.8022

  • human trialHR for cardiovascular death comparing tirzepatide versus controls was 0.9022

  • human trialHR for all-cause death comparing tirzepatide versus controls was 0.8022

  • human trialTirzepatide improves blood pressure23

  • human trialTirzepatide reduces Low-Density Lipoprotein (LDL) cholesterol23

  • human trialTirzepatide reduces triglycerides23

  • human trialTirzepatide efficacy and safety were assessed in phase III SURPASS 1-5 clinical trial program23

  • human trialAt 40 weeks, all tirzepatide doses (5, 10, 15 mg once weekly) were superior to placebo for changes in HbA1c, fasting serum glucose, bodyweight, and HbA1c targets24

  • human trialMean HbA1c decreased from baseline by 1.87% with tirzepatide 5 mg, 1.89% with tirzepatide 10 mg, and 2.07% with tirzepatide 15 mg versus +0.04% with placebo24

  • human trialTreatment differences versus placebo were -1.91% with tirzepatide 5 mg, -1.93% with tirzepatide 10 mg, and -2.11% with tirzepatide 15 mg (all p<0.0001)24

  • human trial87-92% of participants on tirzepatide met HbA1c targets of less than 7.0% versus 20% on placebo24

  • human trial81-86% of participants on tirzepatide met HbA1c targets of 6.5% or less versus 10% on placebo24

  • human trial31-52% of patients on tirzepatide versus 1% on placebo reached an HbA1c of less than 5.7%24

  • human trialTirzepatide induced dose-dependent bodyweight loss ranging from 7.0 to 9.5 kg24

  • human trialMean HbA change with tirzepatide 10 mg at 52 weeks was -2.43% (SD 0.05)25

  • human trialMean HbA change with tirzepatide 15 mg at 52 weeks was -2.58% (SD 0.05)25

  • human trialMean HbA change with glargine at 52 weeks was -1.44% (SD 0.03)25

  • human trialEstimated treatment difference versus glargine was -0.99% (97.5% CI -1.13 to -0.86) for tirzepatide 10 mg25

  • human trialEstimated treatment difference versus glargine was -1.14% (97.5% CI -1.28 to -1.00) for tirzepatide 15 mg25

  • human trialIn a 40-week, phase 3 trial with 1879 patients, tirzepatide at 5 mg, 10 mg, and 15 mg reduced glycated hemoglobin by -2.01, -2.24, and -2.30 percentage points respectively26

  • human trialSemaglutide 1 mg reduced glycated hemoglobin by -1.86 percentage points over 40 weeks26

  • human trialTirzepatide 10 mg and 15 mg were superior to semaglutide 1 mg in glycated hemoglobin reduction with differences of -0.39 and -0.45 percentage points respectively26

  • human trialTirzepatide produced greater body weight reductions than semaglutide: -1.9 kg (5 mg), -3.6 kg (10 mg), and -5.5 kg (15 mg)26

  • human trialTirzepatide was noninferior and superior to semaglutide with respect to mean change in glycated hemoglobin level from baseline to 40 weeks26

  • human studyRecent studies show benefits of tirzepatide in people with metabolic dysfunction-associated steatohepatitis3

  • human studyRecent studies show benefits of tirzepatide in people with heart failure with preserved ejection fraction and obesity3

  • human studyTirzepatide demonstrated cardiovascular protection in people with type 2 diabetes and established atherosclerotic cardiovascular disease3

  • human studyEarly phase trials in T2DM indicate that tirzepatide improves clinical outcomes beyond those achieved by a selective GLP-1 receptor agonist27

  • expert opinionTirzepatide has been reported to have potential cardiovascular benefits in addition to its glucose lowering effects19

How it works

Based on 25 human trial findings, 1 animal finding, 6 in vitro findings and 16 expert opinion findings.

  • human trialTirzepatide pharmacokinetics were well-described by a two-compartment model with first order absorption and elimination4

  • human trialThe glucose-lowering effect observed with tirzepatide, attributed to GIP and GLP-1 receptor agonism, may reflect an added benefit of GIP receptor-mediated insulinotropic action and an increase of insulin sensitivity independent of body weight changes4

  • human trialThe weight loss observed with tirzepatide may be attributed to a combination of the GIP receptor- and GLP-1-receptor-mediated mechanisms regulating satiety and food intake4

  • human trialTirzepatide is a first-in-class glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist5

  • human trialDual GIP/GLP-1 receptor agonist with novel mechanism of action7

  • human trial39-amino-acid synthetic peptide with a C20 fatty diacid side chain attached via a linker at lysine-207

  • human trialApproximately 5-fold greater potency at GIPR relative to native GIP7

  • human trialAbout 0.2-fold the potency of native GLP-1 at GLP-1R7

Show the remaining 40

  • human trialGLP-1R activation: Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite via hypothalamic signaling7

  • human trialGIPR activation: Potentiates insulin secretion, may improve lipid metabolism and fat distribution, enhances central appetite regulation7

  • human trialTirzepatide is a once-weekly dual agonist, acting on glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors10

  • human trialTirzepatide was primarily metabolized via proteolytic cleavage of the amino acid backbone, β-oxidation of the C20 diacid moiety, and amide hydrolysis11

  • human trialTirzepatide is an agonist of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors13

  • human trialTirzepatide is a first-in-class dual incretin agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors14

  • human trialTirzepatide is a glucose dependent insulinotropic polypeptide (GIP)/glucagon-like peptide 1 (GLP-1) receptor agonist16

  • human trialTirzepatide is a novel dual glucose-dependent insulinotropic polypeptide (GIP) receptor and GLP-1 receptor agonist18

  • human trialDifferences in energy intake during ad libitum lunch were not sufficient to explain the different weight outcomes between tirzepatide and semaglutide20

  • human trialTirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist21

  • human trialTirzepatide is a novel, once weekly, dual GIP/GLP-1 receptor agonist22

  • human trialTirzepatide is capable of controlling glucose blood levels by combining dual agonism of GIP and GLP-1 receptors23

  • human trialGIP and GLP-1 are incretin hormones released in the intestine in response to nutrient intake and stimulate pancreatic beta cell activity secreting insulin23

  • human trialGLP-1 reduces food intake and delays gastric emptying23

  • human trialTirzepatide is a dual glucose-dependent insulinotropic polypeptide and GLP-1 receptor agonist24

  • human trialTirzepatide is a novel dual GIP and GLP-1 receptor agonist25

  • human trialTirzepatide is a dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist26

  • animalStudies using animal models of obesity and diabetes have shown that the co-administration of GIP and GLP-1 has synergistic effects in reducing body weight, food consumption, and fat mass19

  • in vitroTirzepatide (LY3298176) is a dual GIP and GLP-1 receptor agonist27

  • in vitroAnalysis reveals a greater degree of engagement of tirzepatide for the GIP receptor than the GLP-1 receptor, indicating an imbalanced mechanism of action27

  • in vitroTirzepatide mimics the actions of native GIP at the GIP receptor but shows bias at the GLP-1 receptor to favor cAMP generation over β-arrestin recruitment27

  • in vitroTirzepatide shows a weaker ability to drive GLP-1 receptor internalization compared with GLP-127

  • in vitroβ-arrestin1 limits the insulin response to GLP-1, but not GIP or tirzepatide27

  • in vitroThe biased agonism of tirzepatide enhances insulin secretion27

  • expert opinionTirzepatide is a drug targeting the receptors of both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)2

  • expert opinionStructural modifications in GLP-1 RAs and tirzepatide include amino acid sequence substitutions, fatty acid conjugation using a linker, and fusion with albumin or the IgG fragment crystallizable (Fc) region, resulting in minimal metabolism and renal excretion2

  • expert opinionTirzepatide is a first-in-class, single-molecule, dual glucose-dependent insulinotropic polypeptide receptor agonist and glucagon-like peptide-1 receptor agonist3

  • expert opinionGIP receptors and GLP-1 receptors are expressed in many organs and tissues in the body and have both overlapping and nonoverlapping expression and function3

  • expert opinionTirzepatide has pleiotropic effects due to its diverse mechanisms of action on glycemic control, body weight regulation, the cardiorenal system, and lipid metabolism3

  • expert opinionTirzepatide is a dual agonist for the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors6

  • expert opinionTirzepatide is the first approved drug to simultaneously activate two separate metabolic receptors — GIP and GLP-18

  • expert opinionTirzepatide is a 39-amino acid synthetic peptide administered as a once-weekly subcutaneous injection8

  • expert opinionTirzepatide is a once-weekly injectable dual glucose-dependent insulinotropic polypeptide (GIP)/GLP1RA15

  • expert opinionTirzepatide is a 39-amino-acid modified peptide with a C20 fatty diacid moiety that enables binding to albumin and prolongs the half-life to achieve once-weekly dosing15

  • expert opinionTirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist17

  • expert opinionTirzepatide is a synthetic peptide composed of 39 amino acids19

  • expert opinionTirzepatide functions as a dual receptor agonist of both the GIP and GLP-1 receptors19

  • expert opinionThe structure of tirzepatide is based on that of the native GIP with the addition of a 20-carbon fatty diacid moiety19

  • expert opinionTirzepatide is a dual GIP/GLP-1 receptor agonist behind brand names like Mounjaro and Zepbound28

  • expert opinionTirzepatide pharmacokinetics follow a two-compartment model with first-order absorption and elimination28

Dosing

Based on 24 human trial findings.

  • human trialTirzepatide is administered as a subcutaneous injection using a pre-filled single-dose pen1

  • human trialTirzepatide available in strengths: 2.5mg/0.5mL, 5mg/0.5mL, 7.5mg/0.5mL, 10mg/0.5mL, 12.5mg/mL, 15mg/0.5mL1

  • human trialThe recommended starting dosage is 2.5 mg s.c. q.w.4

  • human trialAfter 4 weeks, the dose can be increased to 5 mg s.c. q.w.4

  • human trialThe dose may be further increased in 2.5 mg increments after at least 4 weeks on a dose4

  • human trialThe approved maximum dosage is 15 mg subcutaneously once weekly4

  • human trialThe covariate analysis suggested that adjustment of the dose regimen based on demographics or subpopulations was unnecessary4

  • human trialTirzepatide enables sustained exposure with once-weekly subcutaneous dosing5

Show the remaining 16

  • human trialCovariate analysis suggested that adjustment of the dose regimen based on demographics or subpopulations was unnecessary5

  • human trialTirzepatide is administered once weekly via subcutaneous injection with incremental dosage adjustments6

  • human trialOnce-weekly subcutaneous injection for improved adherence7

  • human trial2.5 mg starting dose, escalating to 5-15 mg maintenance7

  • human trialOnce weekly subcutaneous injection7

  • human trialStandard escalation protocol starts at 2.5 mg once weekly for four weeks, then increases by 2.5 mg every four weeks until reaching target maintenance dose8

  • human trialTirzepatide maximum tolerated dose is 10 mg or 15 mg given subcutaneously once weekly9

  • human trialSemaglutide maximum tolerated dose is 1.7 mg or 2.4 mg given subcutaneously once weekly9

  • human trialTirzepatide is approved at the same doses (5, 10 and 15 mg) for both type 2 diabetes (T2D) and chronic weight management10

  • human trialTirzepatide dosing: once-weekly subcutaneous 10 or 15 mg (maximum tolerated dose)12

  • human trialOnce-weekly subcutaneous tirzepatide dosing used at 5 mg, 10 mg, or 15 mg for 52 weeks13

  • human trialTirzepatide supports once-weekly dosing in Chinese patients with T2D16

  • human trialInitial tirzepatide dose was 2.5 mg, which was increased by 2.5 mg every 4 weeks to a maximum final dose of 10.0 mg at week 16 (Cohort 1) or 15.0 mg at week 24 (Cohort 2)16

  • human trialTirzepatide was initiated at 2.5 mg/week and escalated by 2.5 mg every 4 weeks until the assigned dose was achieved21

  • human trialTirzepatide was administered once a week at doses of 5, 10, or 15 mg24

  • human trialTirzepatide dosing was once-per-week subcutaneous injection at 5 mg, 10 mg, or 15 mg25

How the body handles it

Based on 14 human trial findings and 11 expert opinion findings.

  • human trialThe half-life of tirzepatide was ~5 days and enabled sustained exposure with once-weekly subcutaneous dosing4

  • human trialTirzepatide pharmacokinetics were well-described by a two-compartment model with first order absorption and elimination5

  • human trialThe half-life of tirzepatide was ~5 days5

  • human trialEnables binding to albumin for once-weekly dosing pharmacokinetics7

  • human trialHalf-life of approximately 5 days7

  • human trialPeak plasma concentrations occur at approximately 8-72 hours post-injection7

  • human trialHalf-life ~5 days8

  • human trialThe majority of the excreted dose of [14C]-tirzepatide in humans was recovered within 480 h11

Show the remaining 17

  • human trialRenal excretion was identified as a principal route of elimination in all species with approximately 66% of the administered radioactivity recovered in urine11

  • human trialApproximately 33% was eliminated in feces in humans11

  • human trialThe parent drug was the major circulating component in human, rat, and monkey plasma11

  • human trialMetabolites identified in human plasma were similar to circulating metabolites found in rats and monkeys with no circulating metabolites representing >10% of the total radioactive drug-related exposure11

  • human trialIntact tirzepatide was not observed in urine or feces in any species11

  • human trialThe plasma concentration half-life of tirzepatide was approximately 5–6 days16

  • expert opinionNative human GLP-1 has an extremely short half-life of 2 minutes2

  • expert opinionDue to diverse structures, the pharmacokinetic profiles vary, and a prolonged half-life may be associated with an increased risk of adverse events2

  • expert opinionTirzepatide has an amino acid sequence with a C20 fatty diacid moiety that enables albumin binding and prolongs the half-life3

  • expert opinionThe prolonged half-life allows for once-weekly administration in humans3

  • expert opinionThe 20-carbon fatty diacid moiety increases tirzepatide's half-life to 5 days allowing for once-weekly administration19

  • expert opinionTirzepatide has an elimination half-life of approximately 5 days, or 120 hours28

  • expert opinionAfter one half-life, 50% of tirzepatide remains. After two half-lives, 25%. After three, 12.5%. After four, about 6%. After five half-lives, roughly 25 to 30 days, less than 3% remains in circulation28

  • expert opinionAfter about four weeks of consistent weekly injections, tirzepatide reaches steady state28

  • expert opinionAt steady state with weekly dosing, the trough level stays high enough to maintain therapeutic effects throughout the entire dosing interval28

  • expert opinionCentral compartment volume is approximately 2.47 liters per 70 kilograms of body weight28

  • expert opinionPeripheral compartment adds another 3.98 liters to the volume of distribution28

Safety and side effects

Based on 45 human trial findings, 1 human study finding, 1 animal finding and 7 expert opinion findings.

  • human trialThe most commonly reported adverse effects of the drug are gastrointestinal, including nausea, vomiting, and diarrhea6

  • human trialContraindication: Avoid with personal/family history of medullary thyroid carcinoma or MEN2 syndrome; contraindicated in pregnancy7

  • human trialMost side effects are gastrointestinal and concentrated during the dose-escalation phase8

  • human trialThe most common adverse events in both tirzepatide and semaglutide treatment groups were gastrointestinal9

  • human trialMost gastrointestinal adverse events were mild to moderate in severity and occurred primarily during dose escalation9

  • human trialTirzepatide is well-tolerated with a safety profile similar to GLP-1 receptor agonists10

  • human trialMost common adverse events were mostly mild to moderate gastrointestinal events, occurring more commonly with tirzepatide vs placebo12

  • human trialMost common adverse events in the tirzepatide groups were gastrointestinal events, and most were mild or moderate in severity13

Show the remaining 46

  • human trialTirzepatide was generally well tolerated, with a safety profile consistent with that of GLP-1 RAs14

  • human trialTirzepatide was associated with a low risk of clinically significant or severe hypoglycaemia and no increased risk of major adverse cardiovascular events14

  • human trialAdverse events were mostly mild to moderate in severity, with the most common being gastrointestinal events including nausea, diarrhoea, decreased appetite and vomiting14

  • human trialAdverse events with tirzepatide are similar to other approved GLP1RA and are predominantly gastrointestinal (nausea, vomiting)15

  • human trialThe most frequently reported treatment emergent adverse events (TEAEs) among patients receiving tirzepatide were diarrhea and decreased appetite16

  • human trialMost TEAEs were mild and resolved spontaneously with no serious adverse events reported in the tirzepatide groups16

  • human trialContraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)17

  • human trialHas not been studied in patients with a history of pancreatitis17

  • human trialPancreatitis has been reported in clinical trials17

  • human trialConcomitant use with insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia17

  • human trialHypersensitivity reactions have been reported17

  • human trialAcute kidney injury may occur and renal function should be monitored in patients with renal impairment reporting severe adverse gastrointestinal reactions17

  • human trialUse may be associated with gastrointestinal adverse reactions, sometimes severe17

  • human trialHas not been studied in patients with severe gastrointestinal disease17

  • human trialHas not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema17

  • human trialAcute gallbladder disease has occurred in clinical trials17

  • human trialTirzepatide adverse effects are comparable to GLP-1 receptor agonists18

  • human trialThe most common treatment-emergent adverse events in the tirzepatide groups vs placebo group were diarrhea (12%-21% vs 10%) and nausea (13%-18% vs 3%)21

  • human trial10% of participants in the 5-mg tirzepatide group, 12% in the 10-mg tirzepatide group, 18% in the 15-mg tirzepatide group, and 3% in the placebo group had premature treatment discontinuation21

  • human trialTirzepatide did not increase the risk of major cardiovascular events in participants with T2D versus controls22

  • human trialMost frequent adverse events with tirzepatide were mild to moderate and transient gastrointestinal events, including nausea (12-18% vs 6%), diarrhoea (12-14% vs 8%), and vomiting (2-6% vs 2%)24

  • human trialNo clinically significant (<54 mg/dL [<3 mmol/L]) or severe hypoglycaemia were reported with tirzepatide24

  • human trialNausea occurred in 12-23% with tirzepatide versus 2% with glargine25

  • human trialDiarrhoea occurred in 13-22% with tirzepatide versus 4% with glargine25

  • human trialDecreased appetite occurred in 9-11% with tirzepatide versus <1% with glargine25

  • human trialVomiting occurred in 5-9% with tirzepatide versus 2% with glargine25

  • human trialMost gastrointestinal adverse events were mild to moderate and occurred during the dose-escalation phase25

  • human trialHypoglycaemia (glucose <54 mg/dL or severe) occurred in 6-9% with tirzepatide versus 19% with glargine25

  • human trialIn participants not on sulfonylureas, hypoglycaemia occurred in 1-3% with tirzepatide versus 16% with glargine25

  • human trialMACE-4 events occurred in 109 participants with hazard ratio 0.74 (95% CI 0.51-1.08) for tirzepatide versus glargine25

  • human trialDeaths occurred in 25 (3%) participants on tirzepatide and 35 (4%) on glargine during the study25

  • human trialMost common adverse events were gastrointestinal, primarily mild to moderate in severity26

  • human trialNausea occurred in 17-22% of tirzepatide recipients and 18% of semaglutide recipients26

  • human trialDiarrhea occurred in 13-16% of tirzepatide recipients and 12% of semaglutide recipients26

  • human trialVomiting occurred in 6-10% of tirzepatide recipients and 8% of semaglutide recipients26

  • human trialHypoglycemia (blood glucose <54 mg/dL) was reported in 0.6% (5 mg), 0.2% (10 mg), and 1.7% (15 mg) of tirzepatide recipients and 0.4% of semaglutide recipients26

  • human trialSerious adverse events were reported in 5-7% of tirzepatide recipients and 3% of semaglutide recipients26

  • human studySignificant changes in exposure were observed for oral contraceptives following the administration of tirzepatide2

  • animalTirzepatide causes thyroid C-cell tumors in rats17

  • expert opinionClinically significant drug-metabolizing enzyme- and transporter-mediated DDIs are yet to be reported for GLP-1 RAs and tirzepatide2

  • expert opinionMechanism-of-action-mediated DDIs are currently limited to those involving delayed gastric emptying, and most studies have found them to be clinically insignificant2

  • expert opinionTirzepatide has not undergone studies in patients with pancreatitis6

  • expert opinionMounjaro was FDA-approved May 2022 for type 2 diabetes8

  • expert opinionZepbound was FDA-approved November 2023 for chronic weight management8

  • expert opinionHuman relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined17

  • expert opinionGLP-1 receptor agonists have an established safety profile in cardiovascular disease settings19

What people use it for

Based on 14 human trial findings and 12 expert opinion findings.

  • human trialTirzepatide (Mounjaro) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus1

  • human trialTirzepatide is a first-in-class glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist approved for the treatment of type 2 diabetes mellitus4

  • human trialTirzepatide is approved for the treatment of type 2 diabetes mellitus5

  • human trialFDA approved tirzepatide in May 2022 for treating type 2 diabetes mellitus (T2DM)6

  • human trialTirzepatide can demonstrate efficacy in weight loss, leading to its off-label use for obesity treatment6

  • human trialFDA-approved for type 2 diabetes (Mounjaro) and weight management (Zepbound)7

  • human trialFDA approval as Mounjaro in May 2022 for type 2 diabetes mellitus7

  • human trialFDA approval as Zepbound in November 2023 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity7

Show the remaining 18

  • human trialTirzepatide is approved for use as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus in the USA, EU, Japan and other countries14

  • human trialIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus17

  • human trialIs not indicated for use in patients with type 1 diabetes mellitus17

  • human trialTirzepatide is under development for the treatment of type 2 diabetes (T2D) and obesity22

  • human trialFDA approved Tirzepatide subcutaneous injections as monotherapy or combination therapy with diet and physical exercise for glycemic control in patients with diabetes23

  • human trialOther clinical trials are currently underway to evaluate Tirzepatide use in other diseases23

  • expert opinionTirzepatide has been introduced to the market with indications expanded to include treating obesity2

  • expert opinionTirzepatide is approved for the treatment of diabetes3

  • expert opinionTirzepatide is approved for weight management3

  • expert opinionTirzepatide is approved for obstructive sleep apnea3

  • expert opinionUS FDA approved tirzepatide for management of type 2 diabetes in 20223

  • expert opinionUS FDA approved tirzepatide for reduction of excess weight in adults with obesity or overweight in 20233

  • expert opinionUS FDA approved tirzepatide for moderate-to-severe obstructive sleep apnea in people with obesity in 20243

  • expert opinionTirzepatide is not approved for the treatment of type 1 diabetes mellitus (T1DM)6

  • expert opinionGiven the weight loss properties and lack of liver toxicity, it may have an indirect role in the treatment of nonalcoholic fatty liver disease6

  • expert opinionTirzepatide represents a first-in-class agent as a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP1RA to be approved in the USA and Europe for the treatment of T2D15

  • expert opinionTirzepatide is approved for use in Australia, Canada, the European Union, the United Kingdom and the United States15

  • expert opinionTirzepatide is under development for the treatment of type 2 diabetes mellitus (T2DM), obesity, and nonalcoholic steatohepatitis27

Other findings

Based on 3 human trial findings.

  • human trialStore refrigerated at 2-8 degrees C (36-46 degrees F) in the original carton to protect from light7

  • human trialUnopened pens may be stored at room temperature up to 30 degrees C (86 degrees F) for a maximum of 21 days7

  • human trialTirzepatide comes as single-dose prefilled pens and single-dose vials14

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Limited evidence

Some efficacy findings come from very small early trials.

The Chinese phase 1 trial (A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes) randomized only 24 patients (10 per tirzepatide cohort, 4 placebo, 22 completers), whereas pivotal SURPASS/SURMOUNT trials enrolled hundreds to nearly 2000 participants; the same-direction findings carry very different weight given trial size.

Single source

Molecular weight, receptor potency ratios, peak-plasma timing and storage details come from a single vendor wiki.

Figures such as 4813.45 Da molecular weight, ~5-fold GIPR potency vs native GIP, 0.2-fold GLP-1R potency, 8–72 h peak plasma time and 21-day room-temperature storage are reported only by the peptide protocol wiki (Tirzepatide (Mounjaro/Zepbound): Research Guide | Peptide Protocol Wiki) and are not corroborated by the tier 1 clinical or regulatory sources.

Other

Rodent thyroid tumor relevance to humans is undetermined.

Prescribing information (Tirzepatide: A First-in-class Twincretin for the Management of Type 2Diabetes) states tirzepatide causes thyroid C-cell tumors in rats but explicitly notes the human relevance has not been determined, while still imposing an MTC/MEN2 contraindication.

Limited evidence

Cardiovascular benefit is suggested but based on pooled/observational analyses, not a dedicated outcomes trial.

Cardiovascular protection and MACE hazard ratios (Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. pooled analysis HR 0.80, wide confidence intervals crossing 1; Insights into the Mechanism of Action of Tirzepatide: A Narrative Review | Diabetes Therapy | Springer Nature Link observational, The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist expert opinion) suggest no increased risk and possible benefit, but confidence intervals are wide and no dedicated cardiovascular outcomes trial result is reported.

Other

A tier 3 vendor source restates the ~5-day half-life with added clearance modeling.

The seekpeptides article (How long does tirzepatide last: complete half-life and duration guide - SeekPeptides, tier 3) gives 120-hour half-life, 25–30 day clearance and specific compartment volumes; the core ~5-day half-life is corroborated by tier 1 sources, but the detailed clearance percentages and volumes are from the lower-tier vendor source.

What you may have heard

The claim that tirzepatide is about 5 times more potent than natural GIP at the GIP receptor is not supported by the detailed laboratory pharmacology.

The 5-fold figure appears in a vendor-published peptide wiki. The peer-reviewed receptor-pharmacology study that characterized tirzepatide as an 'imbalanced and biased' dual agonist found instead that tirzepatide mimics the actions of native GIP at the GIP receptor — meaning its potency there is roughly comparable to natural GIP, not several times greater. Where tirzepatide clearly differs from the native hormone is at the GLP-1 receptor, where it is markedly weaker than native GLP-1 (on the order of a fifth of the potency). Readers who encounter the 'about 5 times more potent at GIP' claim should treat it cautiously, as it conflicts with the standard description of the molecule as behaving like native GIP at the GIP receptor while being weaker at the GLP-1 receptor.

Using it with other compounds

Check a stack
  • IpamorelinStack with caution

    Worth caution

    Ipamorelin activates the ghrelin receptor (GHS-R1a), which can mildly stimulate appetite — the opposite of tirzepatide's central appetite reduction. While ipamorelin is relatively selective and its appetite effect is modest, the two pull in opposite directions on hunger signaling and this is worth understanding before combining.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The mechanism descriptions clearly establish opposing effects on appetite regulation. Tirzepatide's mechanisms explicitly include 'Appetite reduction' and 'Hypothalamic appetite/satiety signaling' via GLP-1R and GIP receptor activation. Ipamorelin's mechanisms describe activation of the ghrelin receptor (GHSR-1a), which is the natural hunger hormone receptor. The explanation correctly identifies that these represent opposing directions on hunger signaling—tirzepatide suppresses appetite while ipamorelin activates the hunger hormone pathway. This mechanistic opposition justifies the 'caution' relationship type, even though no shared dimensions are claimed. The proposed relationship is grounded in the actual, opposing mechanisms described for both peptides.
  • TesamorelinComplementary

    Worth caution

    Tirzepatide's dual GIP/GLP-1 action reduces fat mass and improves insulin sensitivity through gut-hormone receptors, distinct from tesamorelin's GH axis. The two can converge on visceral/metabolic fat loss, and tirzepatide's insulin-sensitizing effect may counter GH-induced glucose elevation, but blood glucose still warrants monitoring on the combination.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms support a complementary relationship on the shared dimension of lipolysis. Tesamorelin achieves lipolysis through GH axis activation (GHRHR → cAMP → GH release → IGF-1 signaling), with documented reduction of visceral adipose tissue and hepatic fat. Tirzepatide achieves lipolysis through dual GIP/GLP-1 receptor activation leading to body weight and fat mass reduction via appetite suppression and improved insulin sensitivity. The mechanisms are distinct (GH axis vs. gut-hormone receptors) yet both converge on fat loss outcomes. The explanation correctly identifies this as complementary rather than redundant, and the caveat about glucose monitoring reflects the known pharmacology without contradicting the mechanism descriptions provided.

    Shares lipolysis

  • MOTS-cSame downstream effect

    Worth caution

    Tirzepatide (dual GIP/GLP-1 agonist) and MOTS-c both improve insulin sensitivity and reduce fat mass, but through entirely different mechanisms — incretin receptor signaling versus AMPK-driven muscle glucose uptake and fat oxidation. Convergent metabolic output makes them theoretically complementary.

    Tier 4Theoretical — not established
  • SemaglutideSame mechanism

    Research does not support combining these

    Tirzepatide activates the very same GLP-1 receptor as semaglutide (plus the GIP receptor). Running both together is not additive in a useful way — you are hitting the same appetite/insulin pathway twice, which mostly stacks the side effects (nausea, vomiting, delayed gastric emptying, and risk of low blood sugar if combined with other glucose-lowering agents) rather than giving proportionally more benefit. These are alternatives, not a stack: pick one incretin agonist.

    Tier 2Supported by animal / early studies

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish a shared GLP-1 receptor target. Semaglutide is described as a GLP-1 receptor agonist, and tirzepatide is explicitly stated to activate the GLP-1 receptor (in addition to GIP receptor). Both mechanisms document appetite suppression/reduction as a direct effect. The explanation correctly identifies that tirzepatide activates 'the very same GLP-1 receptor as semaglutide' and that this shared pathway (appetite/insulin signaling via GLP-1R) would result in overlapping rather than additive effects. The proposed relationship of 'same_mechanism' with 'appetite_regulation' as the shared dimension is justified by the provided mechanism material showing both peptides target GLP-1R and both produce appetite-related effects through this pathway.

    Timing Do not co-administer; if switching between them, allow a washout and dose-titrate the new agent from a low dose.

    Shares appetite regulation

  • AOD-9604Complementary

    May be complementary

    Tirzepatide lowers body weight and fat mass through dual incretin (GIP/GLP-1) appetite and metabolic effects, whereas AOD-9604 directly stimulates fat-cell lipolysis. The two operate by distinct mechanisms converging on fat reduction.

    Tier 3Largely anecdotal — commonly discussed

    What the research doesn't fully establish

    Both peptides are explicitly tagged with cAMP_PKA pathway activation in their mechanism descriptions. AOD-9604 operates through cAMP elevation and hormone-sensitive lipase activation to stimulate lipolysis. Tirzepatide generates cAMP through biased agonism at GLP-1R (and implicitly GIP receptor signaling). The proposed relationship correctly identifies that they share the cAMP_PKA dimension while operating through distinct upstream mechanisms (beta3-AR vs. GIP/GLP-1 receptors) that converge on fat reduction outcomes. The explanation accurately characterizes the complementary nature: direct lipolysis stimulation versus appetite/metabolic suppression, both reducing body fat through different pathways but a common second messenger system.

    Shares cAMP PKA

  • MK-677Stack with caution

    Worth caution

    MK-677 is a ghrelin-receptor agonist that increases hunger and can raise blood glucose and reduce insulin sensitivity — directly opposing tirzepatide's appetite suppression and glucose-lowering effects. Stacking them works at cross-purposes on both appetite and glycemic control, so their metabolic goals partly cancel out.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The proposed relationship claims MK-677 'can raise blood glucose and reduce insulin sensitivity,' but this is not stated in MK-677's mechanism description. The mechanism provided for MK-677 describes GH/IGF-1 axis activation, increased appetite, and lean mass gain—but does not explicitly mention glucose elevation or insulin sensitivity reduction. While tirzepatide's mechanism clearly includes glucose-dependent insulin secretion, HbA1c reduction, and improved insulin sensitivity, the mechanism material for MK-677 does not establish opposing effects on these parameters. The explanation relies on external pharmacological knowledge rather than the provided mechanism descriptions. Without explicit statements in MK-677's mechanism about glucose or insulin effects, the claimed opposition cannot be judged as supported by the given material.
  • Melanotan IISame downstream effect

    Worth caution

    Melanotan II is a melanocortin (MC4R) agonist whose known side effect is appetite suppression, and tirzepatide also strongly suppresses appetite through hypothalamic satiety signaling. These converge on the same downstream anorexigenic output, so combining them could produce excessive appetite loss and additive nausea.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms clearly establish convergence on cAMP_PKA signaling and appetite regulation. Tirzepatide activates GLP-1R and GIP receptor, generating cAMP through biased agonism (explicitly tagged cAMP_PKA) and produces appetite reduction via hypothalamic appetite/satiety signaling. Melanotan II activates MC4R (among other melanocortin receptors), elevates cAMP through adenylyl cyclase/Gs protein-coupled receptor signaling (explicitly tagged cAMP_PKA), and produces appetite suppression (explicitly tagged appetite_regulation). Both mechanisms independently document cAMP-PKA pathway activation and appetite suppression as downstream effects. The proposed relationship correctly identifies these two shared dimensions as documented in the mechanism material, and the explanation that both converge on anorexigenic output through overlapping signaling cascades is justified by the provided descriptions.

    Shares cAMP PKA · appetite regulation

  • LinaclotideComplementary

    Worth caution

    Like other incretin agonists, tirzepatide slows gastric emptying and frequently causes constipation; linaclotide does the opposite by boosting intestinal fluid secretion and transit, so it can relieve incretin-related constipation. Their opposing GI effects can balance out, but combined they need monitoring to avoid swinging into diarrhea or dehydration.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    The proposed relationship claims complementary opposing GI effects, but the mechanism descriptions do not establish this as a justified pharmacological relationship. While tirzepatide's mechanism does mention 'slowed gastric emptying,' the descriptions do not explicitly state that tirzepatide causes constipation as a direct mechanistic consequence. Linaclotide's mechanisms clearly show increased fluid secretion and accelerated transit. However, the claim that these peptides have 'complementary' mechanisms that 'balance out' relies on external pharmacological knowledge (that incretin agonists cause constipation) rather than being directly supported by the provided mechanism material. The explanation invokes clinical experience and side-effect profiles not present in the mechanism descriptions. Additionally, no shared dimensions are claimed, which further undermines the relationship characterization. The mechanisms describe distinct receptor targets, distinct signaling pathways (cGMP/PKG for linaclotide vs. cAMP/β-arrestin for tirzepatide), and distinct primary effects, without the descriptions themselves establishing a complementary mechanistic relationship.

    Timing Titrate linaclotide against constipation symptoms and monitor for diarrhea.

  • Alpha-MSHSame downstream effect

    Worth caution

    Alpha-MSH suppresses appetite by acting on hypothalamic melanocortin (MC4R) satiety circuits, while tirzepatide reduces appetite through hypothalamic GLP-1/GIP signaling — different upstream receptors that feed into the same central satiety output. The overlapping appetite-suppressing effect means the anorexigenic (and nausea) effects could compound.

    Tier 4Theoretical — not established

    What the research doesn't fully establish

    Both peptides' mechanisms establish cAMP_PKA as a shared downstream pathway that mediates appetite suppression through distinct upstream receptors. Tirzepatide activates GLP-1R and GIP receptor, both of which generate cAMP via adenylyl cyclase (explicitly tagged cAMP_PKA). Alpha-MSH activates MC4R (and other melanocortin receptors) via adenylyl cyclase/cAMP/PKA signaling (explicitly tagged cAMP_PKA). Both peptides' mechanisms describe appetite suppression/satiety effects, and both converge on hypothalamic signaling circuits (tirzepatide: 'Hypothalamic appetite/satiety signaling'; Alpha-MSH: 'MC4R satiety circuits'). The proposed relationship correctly identifies that different upstream receptors (GLP-1R/GIP-R vs MC4R) feed into the same cAMP_PKA-dependent downstream pathway controlling appetite, making this a valid 'same_downstream' relationship with the shared dimension of cAMP_PKA.

    Shares cAMP PKA

Safety and side effects

Safety and side effects

Common adverse effects

Trials and reviews report the most common adverse events with tirzepatide are gastrointestinal (nausea, vomiting, diarrhea, decreased appetite), mostly mild to moderate, transient and concentrated during the dose-escalation phase, with a safety profile consistent with GLP-1 receptor agonists. In the 1879-patient trial, nausea occurred in 17–22% of tirzepatide recipients (vs 18% semaglutide), diarrhea in 13–16% (vs 12%), vomiting in 6–10% (vs 8%), and serious adverse events in 5–7% (vs 3%). In the 478-participant trial, nausea occurred in 12–18% (vs 6% placebo), diarrhoea 12–14% (vs 8%) and vomiting 2–6% (vs 2%). In the 475-participant insulin-glargine add-on trial, diarrhea occurred in 12–21% (vs 10% placebo) and nausea in 13–18% (vs 3%), with premature discontinuation in 10% (5 mg), 12% (10 mg) and 18% (15 mg) versus 3% placebo. In the 2002-participant trial versus insulin glargine, nausea occurred in 12–23% (vs 2%), diarrhoea 13–22% (vs 4%), decreased appetite 9–11% (vs <1%) and vomiting 5–9% (vs 2%). In the small 24-patient Chinese trial, the most frequent events were diarrhea and decreased appetite; most were mild and resolved spontaneously with no serious adverse events in the tirzepatide groups.

Hypoglycemia

A review reports tirzepatide was associated with a low risk of clinically significant or severe hypoglycaemia. In the 478-participant trial no clinically significant (<54 mg/dL) or severe hypoglycaemia was reported. In the 1879-patient trial, hypoglycemia (<54 mg/dL) occurred in 0.6% (5 mg), 0.2% (10 mg) and 1.7% (15 mg) versus 0.4% semaglutide. In the trial versus insulin glargine, hypoglycaemia (<54 mg/dL or severe) occurred in 6–9% of tirzepatide recipients versus 19% glargine. Prescribing information warns that concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia.

Serious warnings and contraindications

Prescribing information reports tirzepatide causes thyroid C-cell tumors in rats, though the human relevance of these rodent tumors has not been determined; it is contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), and in pregnancy. Prescribing information notes tirzepatide has not been studied in patients with a history of pancreatitis, severe gastrointestinal disease, or certain diabetic retinopathy conditions, and that pancreatitis, hypersensitivity reactions, acute kidney injury and acute gallbladder disease have been reported in clinical trials. Prescribing information advises that gastrointestinal adverse reactions may sometimes be severe, with renal function monitoring advised in renal impairment.

Cardiovascular safety

A pooled analysis of seven RCTs reported no increased risk of major adverse cardiovascular events (MACE-4 HR 0.80, 95% CI 0.57–1.11), and a review reports GLP-1 receptor agonists have an established safety profile in cardiovascular disease settings. In the 2002-participant trial the MACE-4 hazard ratio was 0.74 (95% CI 0.51–1.08), with deaths in 25 (3%) tirzepatide versus 35 (4%) glargine participants. These signals derive from pooled and comparator-trial analyses with wide confidence intervals rather than a dedicated cardiovascular outcomes trial.

Reconstitution and handling

Dosing

Tirzepatide has regulatory labels (marketed as Mounjaro and Zepbound), so a recommended dosage exists as a fact about those documents.

Prescribing sources state the recommended starting dosage of tirzepatide is 2.5 mg subcutaneously once weekly, increased to 5 mg after 4 weeks, with further 2.5 mg increments after at least 4 weeks up to a maximum of 15 mg once weekly. A review notes tirzepatide is approved at the same doses (5, 10 and 15 mg) for both type 2 diabetes and chronic weight management. A trial reported the maximum tolerated dose as 10 mg or 15 mg once weekly (compared with 1.7 mg or 2.4 mg once weekly for semaglutide). A population pharmacokinetic covariate analysis suggested that adjustment of the dose regimen based on demographics or subpopulations was unnecessary.

Formulations

FDA documentation states tirzepatide is administered as a subcutaneous injection using a pre-filled single-dose pen (and single-dose vials), available in strengths 2.5 mg/0.5 mL, 5 mg/0.5 mL, 7.5 mg/0.5 mL, 10 mg/0.5 mL, 12.5 mg/mL and 15 mg/0.5 mL (NDA 215866, IND 128801, submission 09/15/2021). As supplied in these pre-filled pens and single-dose vials, the labeled product does not require user reconstitution.

Storage

A peptide protocol wiki advises tirzepatide be stored refrigerated at 2–8°C (36–46°F) in the original carton protected from light, with unopened pens storable at room temperature up to 30°C (86°F) for a maximum of 21 days (this storage detail is a single-source figure from the vendor wiki).

Pharmacokinetic timing

Multiple sources report a plasma half-life of approximately 5 days, and a vendor article (Tier 3) states steady state is reached after about 4 weeks of weekly injections. A peptide protocol wiki reports peak plasma concentrations occur at approximately 8–72 hours post-injection (single-source).

Sources

Ordered by evidence quality — the strongest first.

  1. 215866Orig1s000 Clinical Pharmacology Review(s)(opens in a new tab)
    Tier 1Web · accessdata.fda.gov
  2. A Comprehensive Review on the Pharmacokinetics and Drug−Drug Interac | DDDT | Dove Medical Press(opens in a new tab)
    Tier 1Web · dovepress.com
  3. Insights into the Mechanism of Action of Tirzepatide: A Narrative Review | Diabetes Therapy | Springer Nature Link(opens in a new tab)
    Tier 1Web · link.springer.com
  4. Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  5. S-EPMC10962491 - Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide. - OmicsDI(opens in a new tab)
    Tier 1Web · omicsdi.org
  6. Tirzepatide - StatPearls - NCBI Bookshelf(opens in a new tab)
    Tier 1Web · ncbi.nlm.nih.gov
  7. Tirzepatide (Mounjaro/Zepbound): Research Guide | Peptide Protocol Wiki(opens in a new tab)
    Tier 1Web · peptideprotocolwiki.com
  8. Tirzepatide: Uses, Benefits, FDA Status & Clinics(opens in a new tab)
    Tier 1Web · mypeptidematch.com
  9. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  10. Tirzepatide for overweight and obesity management.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2025
  11. Absorption, distribution, metabolism, and excretion of tirzepatide in humans, rats, and monkeys(opens in a new tab)
    Tier 1Web · doi.org · 2024
  12. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  13. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  14. Tirzepatide: A Review in Type 2 Diabetes.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  15. Tirzepatide for type 2 diabetes(opens in a new tab)
    Tier 1Web · doi.org · 2023
  16. A Phase 1 Multiple Dose Study of Tirzepatide in Chinese Patients with Type 2 Diabetes(opens in a new tab)
    Tier 1Web · doi.org · 2023
  17. Tirzepatide: A First-in-class Twincretin for the Management of Type 2Diabetes(opens in a new tab)
    Tier 1Web · doi.org · 2023
  18. New Drug: Tirzepatide (Mounjaro).(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  19. The Cardiovascular Effect of Tirzepatide: A Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Polypeptide Dual Agonist(opens in a new tab)
    Tier 1Web · doi.org · 2023
  20. Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  21. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  22. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  23. Tirzepatide: A Systematic Update.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  24. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  25. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  26. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2021
  27. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  28. How long does tirzepatide last: complete half-life and duration guide - SeekPeptides(opens in a new tab)
    Tier 3Web · seekpeptides.com
  29. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review(opens in a new tab)
    Tier 3Web · mdpi.com
  30. Tirzepatide: Uses, Interactions, Mechanism of Action(opens in a new tab)
    Tier 4Web · go.drugbank.com